Premium
Lipo‐prostaglandin E 1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes
Author(s) -
Ahn J. H.,
Kim T. Y.,
Kim Y.J.,
Han M. W.,
Yoon T. H.,
Chung J. W.
Publication year - 2006
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2006.01993.x
Subject(s) - medicine , type 2 diabetes , sensorineural hearing loss , diabetes mellitus , hearing loss , prostaglandin e2 , audiology , endocrinology
Background Diabetes mellitus is a risk factor for sudden sensorineural hearing loss (SSNHL), possibly as a result of microvascular damage, increased blood viscosity and embolic and thrombotic episodes. Aim To perform a prospective, randomized clinical trial to determine the therapeutic effect of lipo‐prostaglandin E 1 (lipo‐PGE 1 ) on SSNHL in Korean patients with Type 2 diabetes. Methods The study group consisted of 270 consecutive Korean patients (130 male, 140 female) in whom SSNHL was diagnosed. Patients were classified as diabetic or non‐diabetic by the new American Diabetes Association criteria. With the approval of the institute ethics committee, patients were randomly assigned to treatment with of 10 µg lipo‐PGE 1 (lipo‐PGE 1 group) given as a continuous infusion over 5 days, or saline (placebo group). In addition, all patients studied were treated with 48 mg methylprednisolone for 5 days. Results The overall recovery rates after treatment were 51.5% in diabetic and 64.2% in non‐diabetic patients. In diabetic patients, there was a significantly higher rate of hearing improvement in the lipo‐PGE 1 group (64.7%) compared with the placebo group (37.5%), whereas, in non‐diabetic patients, there was no significant difference in rate of hearing improvement between the lipo‐PGE 1 group (70.3%) and the placebo group (58.3%). Conclusion Lipo‐PGE 1 may have beneficial effects in the treatment of SSNHL in Korean patients with Type 2 diabetes.